Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their experience with a 7600 graft hair transplant using scalp, beard, and chest hair over three procedures, expressing satisfaction with the results despite mixed feedback. They also used finasteride to thicken hair and considered scalp micropigmentation for further improvement.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

A 59-year-old man with significant hair loss has seen some improvement, including reversal of Retrograde Alopecia and darkening of hair, after switching to RU58841 and a new minoxidil base solution with additional ingredients. He also changed from a derma roller to a derma stamp for application.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

RU58841 is generally considered ineffective as a standalone hair loss treatment, with most users combining it with finasteride or dutasteride for better results. Few report success using RU58841 alone.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

After a year on dutasteride and oral minoxidil, the user experienced significant hair regrowth, improving from Norwood 2 to almost Norwood 1. They added RU58841, microneedling, rosemary oil, GHK-Cu, and annurca apple supplement to their regimen and are now noticing hair loss in the temple area.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

A user humorously questions if they should shave their head due to hair loss, mentioning Ronald Reagan's impressive hair genetics. Replies include jokes and comments about jealousy and distrust towards older individuals with full heads of hair.